Medinotec INC 10-Q quarterly reports

Medinotec Inc. announced its first-quarter fiscal year 2026 results, showcasing a 24% increase in revenue and a significant rise in net income driven by improved gross margins and a tax benefit.

Medinotec Inc. reported significant profit growth and substantial debt reduction in its Q3 2025 filing, driven by international sales, despite U.S. revenue decline and tariff concerns.

Medinotec Inc. reported significant revenue growth in Q2 2026, driven by international distribution, but faces challenges from a new U.S. tariff, customer concentration, and ineffective disclosure controls.

Medinotec, Inc. announced a significant 70.5% revenue increase for the quarter ended May 31, 2025, driven by international distribution, but faced gross margin contraction, negative operating cash flow, and a new 30% U.S. tariff on South African imports.

Medinotec Inc. saw a significant increase in revenue for the quarter ended November 30, 2024, primarily driven by its international sales segment and the expansion of its distribution network.

Medinotec Inc. reports a significant increase in revenue for the quarter ended August 31, 2024, primarily driven by international sales and the expansion of its distribution network.

Medinotec Inc. reports a substantial revenue increase for the quarter ended May 31, 2024, primarily driven by new distribution agreements in the cardiology sector.

Medinotec Inc. saw a significant increase in revenue for the quarter ended November 30, 2023, driven by new distribution agreements and U.S. sales of its Trachealator product, but the company's net loss also widened during the period.